We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Morris Brown MD, FRCP, FMedSci

Morris J. Brown MD, FRCP, FMedSci

Professor of Endocrine Hypertension, Queen Mary University of London, William Harvey Heart Centre, Charterhouse Square, London, UK

Morris Brown is Professor of Endocrine Hypertension at the William Harvey Research Institute of Barts and the London, Queen Mary University London, and formerly the foundation Professor of Clinical Pharmacology in the University of Cambridge. His current interest is the translation of molecular mechanisms in Primary Aldosteronism, leading to non-invasive techniques (PET CT, endoscopic ablation) for the cure of hypertension. Papers in Nature Genetics (2013, 2021, 2023), Nature Medicine (2022), N Engl J Med (2015, 2022) and Lancet (2015) report the discoveries of somatic mutations causing aldosterone-producing adenomas, the clinical and molecular differences among the mutations and patients, and the overlap between primary aldosteronism and resistant hypertension. Awards include the Lilly Gold Medal of the British Pharmacological Society (2002), the Walter Somerville Medal of the British Cardiac Society (2006), the RCP/Lancet award (2016), and International Society of Hypertension's Robert Tigerstedt Lifetime Achievement award in 2018.

Recent Contributions to PracticeUpdate:

  1. Efficacy of Baxdrostat for Treatment-Resistant Hypertension